Invivyd IVVD
NASDAQ IVVD
$0.83 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Invivyd (IVVD) Accumulated Expenses (2020 - 2026)

Invivyd's (IVVD) quarterly Accumulated Expenses came in at $19.9 million in Q2 2026, down 21.54% on a YoY basis from $25.3 million in Q2 2025, and up 4.21% quarter-over-quarter from $19.1 million in Q4 2025.

Analysis

Invivyd (IVVD) Accumulated Expenses (2020 - 2026) Analysis & Trends

Invivyd (IVVD) has reported Accumulated Expenses for 7 consecutive years, with $19.9 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Accumulated Expenses fell 21.54% year-over-year to $19.9 million; the trailing twelve-month figure through Jun 2026 stood at $19.9 million (down 21.54% YoY), and the FY2025 full-year result was $19.1 million, down 62.04% from the prior year.
  • Accumulated Expenses improved to $19.9 million in Q2 2026 per IVVD's latest filing, from $19.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $76.5 million in Q1 2022 and bottomed at $14.5 million in Q1 2023.
  • Historically, Accumulated Expenses has averaged $34.0 million across 5 years, with a median of $26.8 million in 2024.
  • The sharpest annual moves came in 2023 and 2024: Accumulated Expenses plunged 81.05% in 2023, then soared 272.23% in 2024.
  • Over 5 years, Accumulated Expenses stood at $21.9 million in 2022, then jumped by 86.48% to $40.9 million in 2023, then gained by 22.85% to $50.2 million in 2024, then sank by 62.04% to $19.1 million in 2025, then gained by 4.21% to $19.9 million in 2026.
  • According to Business Quant data, Accumulated Expenses over the past three periods registered $19.9 million, $19.1 million, and $25.3 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn
10 Invivyd 244.65 Mn 84.57 Mn 13.01 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 19.86 Mn
Dec 31, 2025 19.05 Mn
Sep 30, 2025 25.28 Mn
Jun 30, 2025 25.31 Mn
Mar 31, 2025 39.93 Mn
Dec 31, 2024 50.20 Mn
Sep 30, 2024 59.40 Mn
Jun 30, 2024 26.82 Mn
Mar 31, 2024 34.00 Mn
Dec 31, 2023 40.86 Mn
Sep 30, 2023 15.96 Mn
Jun 30, 2023 26.74 Mn
Mar 31, 2023 14.50 Mn
Dec 31, 2022 21.91 Mn
Sep 30, 2022 28.97 Mn
Jun 30, 2022 52.62 Mn
Mar 31, 2022 76.54 Mn
Dec 31, 2021 56.28 Mn
Sep 30, 2021 35.49 Mn
Jun 30, 2021 27.18 Mn